A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors

Medicinal Research Reviews

Volumn 35, Issue 5, 2015, Pages 1032-1071

  Zheng, Yi Chao ^a   Ma, Jinlian ^a   Wang, Zhiru ^a   Li, Jinfeng ^a   Jiang, Bailing ^a   Zhou, Wenjuan ^a   Shi, Xiaojing ^a   Wang, Xixin ^a   Zhao, Wen ^a   Liu, Hong Min ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Cancer; Histone modification; Inhibitors; LSD1

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; ESTROGEN RECEPTOR; HISTONE DEMETHYLASE; HISTONE LYSINE SPECIFIC DEMETHYLASE 1; HISTONE LYSINE SPECIFIC DEMETHYLASE 1 INHIBITOR; TRANYLCYPROMINE; UNCLASSIFIED DRUG; HISTONE; KDM1A PROTEIN, HUMAN; OXYGEN; PEPTIDE;

ARTICLE; BREAST CANCER; CANCER GROWTH; ENZYME STRUCTURE; ENZYME SUBSTRATE; HISTONE DEMETHYLATION; HUMAN; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN PROTEIN INTERACTION; REACTION ANALYSIS; SIGNAL TRANSDUCTION; STEM CELL; SYSTEMATIC REVIEW (TOPIC); ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CATALYSIS; CELL NUCLEUS; CHEMISTRY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; IC50; METABOLISM; METASTASIS; NEOPLASM; PROTEIN ANALYSIS; PROTEIN TERTIARY STRUCTURE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CATALYSIS; CELL NUCLEUS; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HISTONE DEMETHYLASES; HISTONES; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR DYNAMICS SIMULATION; NEOPLASM METASTASIS; NEOPLASMS; OXYGEN; PEPTIDES; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ESTROGEN; STEM CELLS; TRANSCRIPTION, GENETIC;

EID: 84938751047     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21350     Document Type: Article

References (184)

1. Wu H, Zhang Y. Reversing DNA methylation: Mechanisms, genomics, and biological functions. Cell 2014;156(1-2):45-68.
2. Hill PW, Amouroux R, Hajkova P. DNA demethylation, Tet proteins and 5-hydroxymethylcytosine in epigenetic reprogramming: An emerging complex story. Genomics 2014;104(5):324-333.
3. Ficz G, Gribben JG. Loss of 5-hydroxymethylcytosine in cancer: Cause or consequence? Genomics 2014;104(5):352-357.
4. Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, Yi C, Lindahl T, Pan T, Yang Y-G, He C. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol 2011;7(12):885-887.
5. He CA. RNA epigenetics? Nat Chem Biol 2010;6(12):863-865.
6. Jia GF, Fu Y, He C. Reversible RNA adenosine methylation in biological regulation. Trends Genet 2013;29(2):108-115.
7. Liu N, Pan T. RNA epigenetics. Transl Res 2015;165(1):28-35.
8. Kouzarides T. Chromatin modifications and their function. Cell 2007;128(4):693-705.
9. Peterson CL, Laniel M-A. Histones and histone modifications. Curr Biol 2004;14(14):R546-R551.
10. Woodcock CL, Ghosh RP. Chromatin higher-order structure and dynamics. Cold Spring Harb Perspect Biol 2010;2(5):a000596.
11. Campos EI, Reinberg D. Histones: Annotating chromatin. Annu Rev Genet 2009;43:559-599.
12. Santos-Rosa H, Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 2005;41(16):2381-2402.
13. Cheung P, Lau P. Epigenetic regulation by histone methylation and histone variants. Mol Endocrinol 2005;19(3):563-573.
14. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998;12(5):599-606.
15. Sawicka A, Seiser C. Sensing core histone phosphorylation - A matter of perfect timing. Biochim Biophys Acta 2014;1839(8):711-718.
16. Zhang Y. Transcriptional regulation by histone ubiquitination and deubiquitination. Genes Dev 2003;17(22):2733-2740.
17. Cao J, Yan Q. Histone ubiquitination and deubiquitination in transcription, DNA damage response, and cancer. Front Oncol 2012;2:26. doi: 10.3389/fonc.2012.00026
18. Weake VM, Workman JL. Histone ubiquitination: Triggering gene activity. Mol Cell 29(6):653-663.
19. Nathan D, Sterner DE, Berger SL. Histone modifications: Now summoning sumoylation. Proc Natl Acad Sci 2003;100(23):13118-13120.
20. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004;119(7):941-953.
21. Wood A, Shilatifard A. Posttranslational modifications of histones by methylation. In: Ronald CC, Joan Weliky C, Eds. Advances in Protein Chemistry, Vol. 67. USA: Academic Press, USA; 2004. p 201-222.
22. Thinnes CC, England KS, Kawamura A, Chowdhury R, Schofield CJ, Hopkinson RJ. Targeting histone lysine demethylases - Progress, challenges, and the future. Biochim Biophys Acta 2014;1839(12):1416-1432.
23. Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet 2006;7(9):715-727.
24. Lan F, Nottke AC, Shi Y. Mechanisms involved in the regulation of histone lysine demethylases. Curr Opin Cell Biol 2008;20(3):316-325.
25. Mosammaparast N, Shi Y. Reversal of histone methylation: Biochemical and molecular mechanisms of histone demethylases. Annu Rev Biochem 2010;79:155-179.
26. Lynch JT, Harris WJ, Somervaille TC. LSD1 inhibition: A therapeutic strategy in cancer? Exp Opin Ther Targets 2012;16(12):1239-1249.
27. Mould DP, McGonagle AE, Wiseman DH, Williams EL, Jordan AM. Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: Clinical significance and progress to date. Med Res Rev 2014;35(3):586-618.
28. Suzuki T, Miyata N. Lysine demethylases inhibitors. J Med Chem 2011;54(24):8236-8250.
29. Rotili D, Mai A. Targeting histone demethylases: A new avenue for the fight against cancer. Genes Cancer 2011;2(6):663-679.
30. Hojfeldt JW, Agger K, Helin K. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov 2013;12(12):917-930.
31. Forneris F, Battaglioli E, Mattevi A, Binda C. New roles of flavoproteins in molecular cell biology: Histone demethylase LSD1 and chromatin. FEBS J 2009;276(16):4304-4312.
32. Culhane JC, Cole PA. LSD1 and the chemistry of histone demethylation. Curr Opin Chem Biol 2007;11(5):561-568.
33. Walport LJ, Hopkinson RJ, Schofield CJ. Mechanisms of human histone and nucleic acid demethylases. Curr Opin Chem Biol 2012;16(5-6):525-534.
34. Forneris F, Binda C, Vanoni MA, Battaglioli E, Mattevi A. Human histone demethylase LSD1 reads the histone code. J Biol Chem 2005;280(50):41360-41365.
35. Culhane JC, Szewczuk LM, Liu X, Da G, Marmorstein R, Cole PA. A mechanism-based inactivator for histone demethylase LSD1. J Am Chem Soc 2006;128(14):4536-4537.
36. Yu T, Higashi M, Cembran A, Gao J, Truhlar DG. Concerted hydrogen atom and electron transfer mechanism for catalysis by lysine-specific demethylase. J Phys Chem B 2013;117(28):8422-8429.
37. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, Gunther T, Buettner R, Schule R. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005;437(7057):436-439.
38. Zheng YC, Duan YC, Ma JL, Xu RM, Zi X, Lv WL, Wang MM, Ye XW, Zhu S, Mobley D, Zhu YY, Wang JW, Li JF, Wang ZR, Zhao W, Liu HM. Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration. J Med Chem 2013;56(21):8543-8560.
39. Ma LY, Zheng YC, Wang SQ, Wang B, Wang ZR, Pang LP, Zhang M, Wang JW, Ding L, Li J, Wang C, Hu B, Liu Y, Zhang XD, Wang JJ, Wang ZJ, Zhao W, Liu HM. Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents. J Med Chemistry 2015;58(4):1705-1716.
40. Zhang X, Lu F, Wang J, Yin F, Xu Z, Qi D, Wu X, Cao Y, Liang W, Liu Y, Sun H, Ye T, Zhang H. Pluripotent stem cell protein Sox2 confers sensitivity to LSD1 inhibition in cancer cells. Cell Rep 2013;5(2):445-457.
41. Lan F, Zaratiegui M, Villén J, Vaughn MW, Verdel A, Huarte M, Shi Y, Gygi SP, Moazed D, Martienssen RA, Shi Y. S. pombe LSD1 homologs regulate heterochromatin propagation and euchromatic gene transcription. Mol Cell 2007;26(1):89-101.
42. Opel M, Lando D, Bonilla C, Trewick SC, Boukaba A, Walfridsson J, Cauwood J, Werler PJ, Carr AM, Kouzarides T, Murzina NV, Allshire RC, Ekwall K, Laue ED. Genome-wide studies of histone demethylation catalysed by the fission yeast homologues of mammalian LSD1. PloS One 2007;2(4):e386.
43. Shi YJ, Matson C, Lan F, Iwase S, Baba T, Shi Y. Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell 2005;19(6):857-864.
44. Lee MG, Wynder C, Cooch N, Shiekhattar R. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 2005;437(7057):432-435.
45. Forneris F, Binda C, Dall'Aglio A, Fraaije MW, Battaglioli E, Mattevi A. A highly specific mechanism of histone H3-K4 recognition by histone demethylase LSD1. J Biol Chem 2006;281(46):35289-32595.
46. Wang J, Scully K, Zhu X, Cai L, Zhang J, Prefontaine GG, Krones A, Ohgi KA, Zhu P, Garcia-Bassets I, Liu F, Taylor H, Lozach J, Jayes FL, Korach KS, Glass CK, Fu XD, Rosenfeld MG. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 2007;446(7138):882-887.
47. Liang Y, Vogel JL, Narayanan A, Peng H, Kristie TM. Inhibition of the histone demethylase LSD1 blocks alpha-herpesvirus lytic replication and reactivation from latency. Nat Med 2009;15(11):1312-1317.
48. Garcia-Bassets I, Kwon YS, Telese F, Prefontaine GG, Hutt KR, Cheng CS, Ju BG, Ohgi KA, Wang J, Escoubet-Lozach L, Rose DW, Glass CK, Fu XD, Rosenfeld MG. Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell 2007;128(3):505-518.
49. Laurent B, Ruitu L, Murn J, Hempel K, Ferrao R, Xiang Y, Liu S, Garcia BA, Wu H, Wu F, Steen H, Shi Y. A specific LSD1/KDM1A isoform regulates neuronal differentiation through H3K9 demethylation. Mol Cell 2015;57(6):957-970.
50. Chen Y, Yang Y, Wang F, Wan K, Yamane K, Zhang Y, Lei M. Crystal structure of human histone lysine-specific demethylase 1 (LSD1). Proc Natl Acad Sci USA 2006;103(38):13956-13961.
51. Tochio N, Umehara T, Koshiba S, Inoue M, Yabuki T, Aoki M, Seki E, Watanabe S, Tomo Y, Hanada M, Ikari M, Sato M, Terada T, Nagase T, Ohara O, Shirouzu M, Tanaka A, Kigawa T, Yokoyama S. Solution structure of the SWIRM domain of human histone demethylase LSD1. Structure 2006;14(3):457-468.
52. Ferrari-Amorotti G, Fragliasso V, Esteki R, Prudente Z, Soliera AR, Cattelani S, Manzotti G, Grisendi G, Dominici M, Pieraccioli M, Raschella G, Chiodoni C, Colombo MP, Calabretta B. Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion. Cancer Res 2013;73(1):235-245.
53. Hou H, Yu H. Structural insights into histone lysine demethylation. Curr Opin Struct Biol 2010;20(6):739-748.
54. Vellore N, Baron R. Molecular dynamics simulations indicate an induced-fit mechanism for LSD1/CoREST-H3-histone molecular recognition. BMC Biophys 2013;6(1):15.
55. Baron R, Vellore NA. LSD1/CoREST reversible opening-closing dynamics: Discovery of a nanoscale clamp for chromatin and protein binding. Biochemistry 2012;51(15):3151-3153.
56. Robertson JC, Hurley NC, Tortorici M, Ciossani G, Borrello MT, Vellore NA, Ganesan A, Mattevi A, Baron R. Expanding the druggable space of the LSD1/CoREST epigenetic target: New potential binding regions for drug-like molecules, peptides, protein partners, and chromatin. PLoS Comput Biol 2013;9(7):e1003158.
57. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T, Berger SL. p53 is regulated by the lysine demethylase LSD1. Nature 2007;449(7158):105-108.
58. Kontaki H, Talianidis I. Lysine methylation regulates E2F1-induced cell death. Mol Cell 2010;39(1):152-160.
59. Wang J, Hevi S, Kurash JK, Lei H, Gay F, Bajko J, Su H, Sun W, Chang H, Xu G, Gaudet F, Li E, Chen T. The lysine demethylase LSD1 is required for maintenance of global DNA methylation. Nat Genet 2009;41(1):125-129.
60. Cho HS, Suzuki T, Dohmae N, Hayami S, Unoki M, Yoshimatsu M, Toyokawa G, Takawa M, Chen T, Kurash JK, Field HI, Ponder BA, Nakamura Y, Hamamoto R. Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res 2011;71(3):655-660.
61. Saleque S, Kim J, Rooke HM, Orkin SH. Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. Mol Cell 2007;27(4):562-572.
62. Roizman B. The checkpoints of viral gene expression in productive and latent infection: The role of the HDAC/CoREST/LSD1/REST repressor complex. J Virology 2011;85(15):7474-7482.
63. Su ST, Ying HY, Chiu YK, Lin FR, Chen MY, Lin KI. Involvement of histone demethylase LSD1 in blimp-1-mediated gene repression during plasma cell differentiation. Mol Cell Biol 2009;29(6):1421-1431.
64. Yokoyama A, Igarashi K, Sato T, Takagi K, Otsuka IM, Shishido Y, Baba T, Ito R, Kanno J, Ohkawa Y, Morohashi K, Sugawara A. Identification of myelin transcription factor 1 (MyT1) as a subunit of the neural cell type-specific lysine-specific demethylase 1 (LSD1) complex. J Biol Chem 2014;289(26):18152-18162.
65. Lin Y, Wu Y, Li J, Dong C, Ye X, Chi YI, Evers BM, Zhou BP. The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. EMBO J 2010;29(11):1803-1816.
66. Wang Y, Zhang H, Chen Y, Sun Y, Yang F, Yu W, Liang J, Sun L, Yang X, Shi L, Li R, Li Y, Zhang Y, Li Q, Yi X, Shang Y. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 2009;138(4):660-672.
67. Li Q, Shi L, Gui B, Yu W, Wang J, Zhang D, Han X, Yao Z, Shang Y. Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14. Cancer Res 2011;71(21):6899-6908.
68. Ouyang H, Qin Y, Liu Y, Xie Y, Liu J. Prox1 directly interacts with LSD1 and recruits the LSD1/NuRD complex to epigenetically co-repress CYP7A1 transcription. PloS One 2013;8(4):e62192.
69. Chau CM, Deng Z, Kang H, Lieberman PM. Cell cycle association of the retinoblastoma protein Rb and the histone demethylase LSD1 with the Epstein-Barr virus latency promoter Cp. J Virol 2008;82(7):3428-3437.
70. Lee SW, Cho YS, Na JM, Park UH, Kang M, Kim EJ, Um SJ. ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1. J Biol Chem 2010;285(1):18-29.
71. Mulligan P, Yang F, Di Stefano L, Ji JY, Ouyang J, Nishikawa JL, Toiber D, Kulkarni M, Wang Q, Najafi-Shoushtari SH, Mostoslavsky R, Gygi SP, Gill G, Dyson NJ, Naar AM. A SIRT1-LSD1 corepressor complex regulates Notch target gene expression and development. Mol Cell 2011;42(5):689-699.
72. Yang P, Wang Y, Chen J, Li H, Kang L, Zhang Y, Chen S, Zhu B, Gao S. RCOR2 is a subunit of the LSD1 complex that regulates ESC property and substitutes for SOX2 in reprogramming somatic cells to pluripotency. Stem cells 2011;29(5):791-801.
73. LeDouce V, Colin L, Redel L, Cherrier T, Herbein G, Aunis D, Rohr O, VanLint C, Schwartz C. LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional silencing. Nucleic Acids Res 2012;40(5):1904-1915.
74. Kim J, Park UH, Moon M, Um SJ, Kim EJ. Negative regulation of ERalpha by a novel protein CAC1 through association with histone demethylase LSD1. FEBS Lett 2013;587(1):17-22.
75. Porro A, Feuerhahn S, Lingner J. TERRA-reinforced association of LSD1 with MRE11 promotes processing of uncapped telomeres. Cell Rep 2014;6(4):765-776.
76. Karytinos A, Forneris F, Profumo A, Ciossani G, Battaglioli E, Binda C, Mattevi A. A novel mammalian flavin-dependent histone demethylase. J Biol Chem 2009;284(26):17775-17782.
77. Ciccone DN, Su H, Hevi S, Gay F, Lei H, Bajko J, Xu G, Li E, Chen T. KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints. Nature 2009;461(7262):415-418.
78. Yang Z, Jiang J, Stewart DM, Qi S, Yamane K, Li J, Zhang Y, Wong J. AOF1 is a histone H3K4 demethylase possessing demethylase activity-independent repression function. Cell Res 2010;20(3):276-287.
79. vanEssen D, Zhu Y, Saccani S. A feed-forward circuit controlling inducible NF-kappaB target gene activation by promoter histone demethylation. Mol Cell 2010;39(5):750-760.
80. Fang R, Barbera AJ, Xu Y, Rutenberg M, Leonor T, Bi Q, Lan F, Mei P, Yuan GC, Lian C, Peng J, Cheng D, Sui G, Kaiser UB, Shi Y, Shi YG. Human LSD2/KDM1b/AOF1 regulates gene transcription by modulating intragenic H3K4me2 methylation. Mol Cell 2010;39(2):222-233.
81. Fang R, Chen F, Dong Z, Hu D, Barbera AJ, Clark EA, Fang J, Yang Y, Mei P, Rutenberg M, Li Z, Zhang Y, Xu Y, Yang H, Wang P, Simon MD, Zhou Q, Li J, Marynick MP, Li X, Lu H, Kaiser UB, Kingston RE, Xu Y, Shi YG. LSD2/KDM1B and its cofactor NPAC/GLYR1 endow a structural and molecular model for regulation of H3K4 demethylation. Mol Cell 2013;49(3):558-570.
82. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995;83(6):841-850.
83. Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato AC. Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 1999;18(46):6322-6329.
84. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000;14(2):121-141.
85. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002;108(4):465-474.
86. Yamane K, Toumazou C, Tsukada Y-I, Erdjument-Bromage H, Tempst P, Wong J, Zhang Y. JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell 2006;125(3):483-495.
87. Wissmann M, Yin N, Muller JM, Greschik H, Fodor BD, Jenuwein T, Vogler C, Schneider R, Gunther T, Buettner R, Metzger E, Schule R. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 2007;9(3):347-353.
88. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu XS, Brown M, Balk SP. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 2011;20(4):457-471.
89. Willmann D, Lim S, Wetzel S, Metzger E, Jandausch A, Wilk W, Jung M, Forne I, Imhof A, Janzer A, Kirfel J, Waldmann H, Schule R, Buettner R. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int J Cancer 2012;131(11):2704-2709.
90. Lim S, Janzer A, Becker A, Zimmer A, Schule R, Buettner R, Kirfel J. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 2010;31(3):512-520.
91. Pollock JA, Larrea MD, Jasper JS, McDonnell DP, McCafferty DG. Lysine-specific histone demethylase 1 inhibitors control breast cancer proliferation in ERalpha-dependent and -independent manners. ACS Chem Biol 2012;7(7):1221-1231.
92. Serce N, Gnatzy A, Steiner S, Lorenzen H, Kirfel J, Buettner R. Elevated expression of LSD1 (lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast. BMC Clin Pathol 2012;12:13.
93. Yu SE, Jang YK. The histone demethylase LSD1 is required for estrogen-dependent S100A7 gene expression in human breast cancer cells. Biochem Biophys Res Commun 2012;427(2):336-342.
94. Lin T, Ponn A, Hu X, Law BK, Lu J. Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition. Oncogene 2010;29(35):4896-4904.
95. Shi Y. Histone lysine demethylases: Emerging roles in development, physiology and disease. Nat Rev Genet 2007;8(11):829-833.
96. Foster CT, Dovey OM, Lezina L, Luo JL, Gant TW, Barlev N, Bradley A, Cowley SM. Lysine-specific demethylase 1 regulates the embryonic transcriptome and CoREST stability. Mol Cell Biol 2010;30(20):4851-4863.
97. Rudolph T, Yonezawa M, Lein S, Heidrich K, Kubicek S, Schäfer C, Phalke S, Walther M, Schmidt A, Jenuwein T. Heterochromatin formation in Drosophila is initiated through active removal of H3K4 methylation by the LSD1 homolog SU (VAR) 3-3. Mol Cell 2007;26(1):103-115.
98. Di Stefano L, Ji JY, Moon NS, Herr A, Dyson N. Mutation of Drosophila LSD1 disrupts H3-K4 methylation, resulting in tissue-specific defects during development. Curr Biol 2007;17(9):808-812.
99. Katz DJ, Edwards TM, Reinke V, Kelly WG. A C. elegans LSD1 demethylase contributes to germline immortality by reprogramming epigenetic memory. Cell 2009;137(2):308-320.
100. Musri MM, Carmona MC, Hanzu FA, Kaliman P, Gomis R, Párrizas M. Histone demethylase LSD1 regulates adipogenesis. J Biol Chem 2010;285(39):30034-30041.
101. Choi J, Jang H, Kim H, Kim S-T, Cho E-J, Youn H-D. Histone demethylase LSD1 is required to induce skeletal muscle differentiation by regulating myogenic factors. Biochem Biophys Res Commun 2010;401(3):327-332.
102. Kim J, Orkin SH. Embryonic stem cell-specific signatures in cancer: insights into genomic regulatory networks and implications for medicine. Genome Med 2011;3(11):75-75.
103. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005;122(6):947-956.
104. Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB, Wong E, Orlov YL, Zhang W, Jiang J. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 2008;133(6):1106-1117.
105. Kim J, Chu J, Shen X, Wang J, Orkin SH. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 2008;132(6):1049-1061.
106. Loh Y-H, Wu Q, Chew J-L, Vega VB, Zhang W, Chen X, Bourque G, George J, Leong B, Liu J. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 2006;38(4):431-440.
107. Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S, Guenther MG, Johnston WK, Wernig M, Newman J. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 2008;134(3):521-533.
108. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 2004;10(1):55-63.
109. Niwa H, Burdon T, Chambers I, Smith A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev 1998;12(13):2048-2060.
110. Adamo A, Barrero MJ, Belmonte JCI. LSD1 and pluripotency: A new player in the network. Cell Cycle 2011;10(19):3215-3216.
111. Whyte WA, Bilodeau S, Orlando DA, Hoke HA, Frampton GM, Foster CT, Cowley SM, Young RA. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature 2012;482(7384):221-225.
112. Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol 2006;13(6):563-567.
113. Kerenyi MA, Shao Z, Hsu Y-J, Guo G, Luc S, O'Brien K, Fujiwara Y, Peng C, Nguyen M, Orkin SH. Histone demethylase LSD1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. Elife 2013;2:e00633.
114. Zhu D, Holz S, Metzger E, Pavlovic M, Jandausch A, Jilg C, Galgoczy P, Herz C, Moser M, Metzger D, Gunther T, Arnold SJ, Schule R. Lysine-specific demethylase 1 regulates differentiation onset and migration of trophoblast stem cells. Nat Commun 2014;5:3174.
115. Sun G, Ye P, Murai K, Lang M-F, Li S, Zhang H, Li W, Fu C, Yin J, Wang A, Ma X, Shi Y. miR-137 forms a regulatory loop with nuclear receptor TLX and LSD1 in neural stem cells. Nat Commun 2011;2:529.
116. Althoff K, Beckers A, Odersky A, Mestdagh P, Koster J, Bray IM, Bryan K, Vandesompele J, Speleman F, Stallings RL, Schramm A, Eggert A, Sprussel A, Schulte JH. MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A. Int J Cancer 2013;133(5):1064-1073.
117. Yang H, Li Q, Zhao W, Yuan D, Zhao H, Zhou Y. miR-329 suppresses the growth and motility of neuroblastoma by targeting KDM1A. FEBS Lett 2014;588(1):192-197.
118. Wu Y, Wang Y, Yang Xiuwei H, Kang T, Zhao Y, Wang C, Evers BM, Zhou Binhua P. The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells. Cell Rep 2013;5(1):224-236.
119. Han X, Gui B, Xiong C, Zhao L, Liang J, Sun L, Yang X, Yu W, Si W, Yan R, Yi X, Zhang D, Li W, Li L, Yang J, Wang Y, Sun Yi E, Zhang D, Meng A, Shang Y. Destabilizing LSD1 by Jade-2 promotes neurogenesis: An antibraking system in neural development. Mol Cell 2014;55(3):482-494.
120. Huang Y, Vasilatos SN, Boric L, Shaw PG, Davidson NE. Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. Breast Cancer Res Treat 2012;131(3):777-789.
121. Chen C, Zhao M, Yin N, He B, Wang B, Yuan Y, Yu F, Hu J, Yin B, Lu Q. Abnormal histone acetylation and methylation levels in esophageal squamous cell carcinomas. Cancer Investig 2011;29(8):548-556.
122. Ding J, Zhang ZM, Xia Y, Liao GQ, Pan Y, Liu S, Zhang Y, Yan ZS. LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer. British J Cancer 2013;109(4):994-1003.
123. Jin L, Hanigan CL, Wu Y, Wang W, Park BH, Woster PM, Casero RA. Loss of LSD1 (lysine-specific demethylase 1) suppresses growth and alters gene expression of human colon cancer cells in a p53- and DNMT1(DNA methyltransferase 1)-independent manner. Biochem J 2013;449(2):459-568.
124. Rao M, Chinnasamy N, Hong JA, Zhang Y, Zhang M, Xi S, Liu F, Marquez VE, Morgan RA, Schrump DS. Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: Implications for adoptive immunotherapy of cancer. Cancer Res 2011;71(12):4192-4204.
125. Bennani-Baiti IM, Machado I, Llombart-Bosch A, Kovar H. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol 2012;43(8):1300-1307.
126. Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, Nakamura Y, Hamamoto R. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 2011;128(3):574-586.
127. Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X, Song Y. Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PloS One 2012;7(4):e35065.
128. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J, Metzger E, Schule R, Buettner R. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006;66(23):11341-11347.
129. Kauffman EC, Robinson BD, Downes MJ, Powell LG, Lee MM, Scherr DS, Gudas LJ, Mongan NP. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog 2011;50(12):931-944.
130. Lohse B, Kristensen JL, Kristensen LH, Agger K, Helin K, Gajhede M, Clausen RP. Inhibitors of histone demethylases. Bioorg Med Chem 2011;19(12):3625-3636.
131. Lokken AA, Zeleznik-Le NJ. Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML. Cancer Cell 2012;21(4):451-453.
132. Schenk T, Chen WC, Gollner S, Howell L, Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, Casero RA Jr., Marton L, Woster P, Minden MD, Dugas M, Wang JC, Dick JE, Muller-Tidow C, Petrie K, Zelent A. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 2012;18(4):605-611.
133. Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, Ciceri F, Blaser JG, Greystoke BF, Jordan AM, Miller CJ, Ogilvie DJ, Somervaille TC. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012;21(4):473-487.
134. Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, Iyer SP, Bearss D, Bhalla KN. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia 2014;28(11):2155-2164.
135. Murray-Stewart T, Woster PM, Casero RA Jr. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines. Amino Acids 2014;46(3):585-594.
136. Sakane N, Kwon H-S, Pagans S, Kaehlcke K, Mizusawa Y, Kamada M, Lassen KG, Chan J, Greene WC, Schnoelzer M, Ott M. Activation of HIV transcription by the viral tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1). PLoS Pathog 2011;7(8):e1002184.
137. Gu H, Roizman B. Engagement of the lysine-specific demethylase/HDAC1/CoREST/REST complex by herpes simplex virus 1. J Virol 2009;83(9):4376-4385.
138. Zhou G, Du T, Roizman B. The role of the CoREST/REST repressor complex in herpes simplex virus 1 productive infection and in latency. Viruses 2013;5(5):1208-1218.
139. Zhou G, Te D, Roizman B. The CoREST/REST repressor is both necessary and inimical for expression of herpes simplex virus genes. MBio 2011;2(1):e00313-00310.
140. Du T, Zhou G, Khan S, Gu H, Roizman B. Disruption of HDAC/CoREST/REST repressor by dnREST reduces genome silencing and increases virulence of herpes simplex virus. Proc Natl Acad Sci 2010;107(36):15904-15909.
141. Hino S, Sakamoto A, Nagaoka K, Anan K, Wang Y, Mimasu S, Umehara T, Yokoyama S, Kosai K, Nakao M. FAD-dependent lysine-specific demethylase-1 regulates cellular energy expenditure. Nat Commun 2012;3:758.
142. Duteil D, Metzger E, Willmann D, Karagianni P, Friedrichs N, Greschik H, Günther T, Buettner R, Talianidis I, Metzger D, Schüle R. LSD1 promotes oxidative metabolism of white adipose tissue. Nat Commun 2014;5. doi: 10.1038/ncomms5093
143. Ueda R, Suzuki T, Mino K, Tsumoto H, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Miyata N. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J Am Chem Soc 2009;131(48):17536-17537.
144. Gooden DM, Schmidt DM, Pollock JA, Kabadi AM, McCafferty DG. Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B. Bioorg Med Chem Lett 2008;18(10):3047-3051.
145. Son SY, Ma J, Kondou Y, Yoshimura M, Yamashita E, Tsukihara T. Structure of human monoamine oxidase A at 2.2-A resolution: The control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci USA 2008;105(15):5739-5744.
146. Binda C, Li M, Hubalek F, Restelli N, Edmondson DE, Mattevi A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc Natl Acad Sci USA 2003;100(17):9750-9755.
147. Khan MNA, Tsumoto H, Itoh Y, Ota Y, Suzuki M, Ogasawara D, Nakagawa H, Mizukami T, Miyata N, Suzuki T. Design, synthesis, and biological activity of N-alkylated analogue of NCL1, a selective inhibitor of lysine-specific demethylase 1. MedChemComm 2015;6:407-412.
148. Benelkebir H, Hodgkinson C, Duriez PJ, Hayden AL, Bulleid RA, Crabb SJ, Packham G, Ganesan A. Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors. Bioorg Med Chem 2011;19(12):3709-3716.
149. Binda C, Valente S, Romanenghi M, Pilotto S, Cirilli R, Karytinos A, Ciossani G, Botrugno OA, Forneris F, Tardugno M, Edmondson DE, Minucci S, Mattevi A, Mai A. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J Am Chem Soc 2010;132(19):6827-6833.
150. Valente S, Rodriguez V, Mercurio C, Vianello P, Saponara B, Cirilli R, Ciossani G, Labella D, Marrocco B, Ruoppolo G. Pure diastereomers of a tranylcypromine-based LSD1 inhibitor: Enzyme selectivity and in cell studies. ACS Med Chem Lett 2014;6(2):173-177.
151. Rodriguez V, Valente S, Rovida S, Rotili D, Stazi G, Lucidi A, Ciossani G, Mattevi A, Botrugno OA, Dessanti P. Pyrrole-and indole-containing tranylcypromine derivatives as novel lysine-specific demethylase 1 inhibitors active on cancer cells. MedChemComm 2015;14:665-670.
152. Mimasu S, Umezawa N, Sato S, Higuchi T, Umehara T, Yokoyama S. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1. Biochemistry 2010;49(30):6494-6503.
153. Rotili D, Tomassi S, Conte M, Benedetti R, Tortorici M, Ciossani G, Valente S, Marrocco B, Labella D, Novellino E, Mattevi A, Altucci L, Tumber A, Yapp C, King ON, Hopkinson RJ, Kawamura A, Schofield CJ, Mai A. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. J Med Chem 2014;57(1):42-55.
154. Castro-Palomino Laria J, Fyfe MCT, Martinell Pedemonte M, Ortega Munoz A, Valls Vidal N. Preparation of cyclopropylamine compounds as inhibitors of oxidases. Patent WO 2012/045883 A1, Oryzon Genomics SA., 2012.
155. Ortega Munoz A, Castro-Palomino Laria J, Fyfe MCT. Preparation of heteroaryl cyclopropylamines as selective lysine specific demethylase-1 inhibitors, for treating cancer and viral infections. Patent WO 2011/131697 A1, Oryzon Genomics SA., 2011.
156. Fyfe MCT, Maes T, Martinell Pedemonte M, Tirapu Fernandez De La Cuesta I. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders. Patent WO 2012/107499 A1, Oryzon Genomics SA., 2012.
157. Johnson NW, Kasparec J, Miller WH, Rouse MB, Suarez D, Tian X. Preparation of cyclopropylamines as LSD1 inhibitors in the treatment of cancer. Patent WO 2012/135113 A2, GlaxoSmithKline LLC. 2012.
158. Mohammad H, Smitheman K, vanAller G, Cusan M, Kamat S, Liu Y, Johnson N, Hann C, Armstrong S, Kruger R. Novel anti-tumor activity of targeted LSD1 inhibition by GSK2879552. Eur J Cancer 2014;50:72.
159. Vianello P, Thaler F, Botrugno OA, Cappa A, Dessanti P, Meroni G, Trifiro P, Villa M, Varasi M, Mercurio C, Ciossani G, Tortorici M, Mai A, Valente S, Mattevi A, Minucci S. Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: A novel class of irreversible inhibitors of histone demethylase KDM1A. Eur J Med Chem 2014;86C:352-363.
160. Pieroni M, Annunziato G, Azzali E, Dessanti P, Mercurio C, Meroni G, Trifiró P, Vianello P, Villa M, Beato C, Varasi M, Costantino G. Further insights into the SAR of α-substituted cyclopropylamine derivatives as inhibitors of histone demethylase KDM1A. Eur J Med Chem 2015;92(0):377-386.
161. Prusevich P, Kalin JH, Ming SA, Basso M, Givens J, Li X, Hu J, Taylor MS, Cieniewicz AM, Hsiao PY, Huang R, Roberson H, Adejola N, Avery LB, Casero RA Jr., Taverna SD, Qian J, Tackett AJ, Ratan RR, McDonald OG, Feinberg AP, Cole PA. A selective phenelzine analogue inhibitor of histone demethylase LSD1. ACS Chem Biol 2014;9(6):1284-1293.
162. Schmidt DM, McCafferty DG. Trans-2-phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 2007;46(14):4408-4416.
163. Szewczuk LM, Culhane JC, Yang M, Majumdar A, Yu H, Cole PA. Mechanistic analysis of a suicide inactivator of histone demethylase LSD1. Biochemistry 2007;46(23):6892-6902.
164. Schmitt ML, Hauser A-T, Carlino L, Pippel M, Schulz-Fincke J, Metzger E, Willmann D, Yiu T, Barton M, Schüle R. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity. J Med Chem 2013;56(18):7334-7342.
165. Ma LY, Zheng YC, Wang SQ, Wang B, Wang ZR, Pang LP, Zhang M, Wang JW, Ding L, Li J, Wang C, Hu B, Liu Y, Zhang XD, Wang JJ, Wang ZJ, Zhao W, Liu HM. Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents. J Med Chem 2015;58(4):1705-1716.
166. Sorna V, Theisen ER, Stephens B, Warner SL, Bearss DJ, Vankayalapati H, Sharma S. High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors. J Med Chemistry 2013;56(23):9496-9508.
167. Forneris F, Binda C, Adamo A, Battaglioli E, Mattevi A. Structural basis of LSD1-CoREST selectivity in histone H3 recognition. J Biol Chem 2007;282(28):20070-20074.
168. Tortorici M, Borrello MT, Tardugno M, Chiarelli LR, Pilotto S, Ciossani G, Vellore NA, Bailey SG, Cowan J, O'Connell M, Crabb SJ, Packham G, Mai A, Baron R, Ganesan A, Mattevi A. Protein recognition by short peptide reversible inhibitors of the chromatin-modifying LSD1/CoREST lysine demethylase. ACS Chem Biol 2013;8(8):1677-1682.
169. Kumarasinghe IR, Woster PM. Synthesis and evaluation of novel cyclic peptide inhibitors of lysine-specific demethylase 1. ACS Med Chem Lett 2013;5(1):29-33.
170. Huang Y, Greene E, Murray Stewart T, Goodwin AC, Baylin SB, Woster PM, Casero RA Jr. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci USA 2007;104(19):8023-8028.
171. Huang Y, Stewart TM, Wu Y, Baylin SB, Marton LJ, Perkins B, Jones RJ, Woster PM, Casero RA, Jr. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res 2009;15(23):7217-7228.
172. Sharma SK, Wu Y, Steinbergs N, Crowley ML, Hanson AS, Casero RA, Woster PM. (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. J Med Chem 2010;53(14):5197-5212.
173. Huang Z, Li S, Song W, Li X, Li Q, Zhang Z, Han Y, Zhang X, Miao S, Du R, Wang L. Lysine-specific demethylase 1 (LSD1/KDM1A) contributes to colorectal tumorigenesis via activation of the Wnt/Β-catenin pathway by down-regulating dickkopf-1 (DKK1). PloS One 2013;8(7):e70077.
174. Wang J, Lu F, Ren Q, Sun H, Xu Z, Lan R, Liu Y, Ward D, Quan J, Ye T, Zhang H. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res 2011;71(23):7238-7249.
175. Hazeldine S, Pachaiyappan B, Steinbergs N, Nowotarski S, Hanson AS, Casero RA Jr., Woster PM. Low molecular weight amidoximes that act as potent inhibitors of lysine-specific demethylase 1. J Med Chem 2012;55(17):7378-7391.
176. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46(1-3):3-26.
177. Dulla B, Kirla KT, Rathore V, Deora GS, Kavela S, Maddika S, Chatti K, Reiser O, Iqbal J, Pal M. Synthesis and evaluation of 3-amino/guanidine substituted phenyl oxazoles as a novel class of LSD1 inhibitors with anti-proliferative properties. Org Biomol Chem 2013;11(19):3103-3107.
178. Hitchin JR, Blagg J, Burke R, Burns S, Cockerill MJ, Fairweather EE, Hutton C, Jordan AM, McAndrew C, Mirza A. Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments. MedChemComm 2013;4(11):1513-1522.
179. Ye X-W, Zheng Y-C, Duan Y-C, Wang M-M, Yu B, Ren J-L, Ma J-L, Zhang E, Liu H-M. Synthesis and biological evaluation of coumarin-1, 2, 3-triazole-dithiocarbamate hybrids as potent LSD1 inhibitors. MedChemComm 2014;5(5):650-654.
180. Kutz CJ, Holshouser SL, Marrow EA, Woster PM. 3, 5-Diamino-1, 2, 4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors. MedChemComm 2014(5):1863-1870.
181. Vankayalapati H, Sorna V, Warner SL, Stephens B, Bearss DJ, Sharma S. Preparation of substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors. Patent US 2014/0163017 A1, University of Utah. 2014.
182. Vankayalapati H, Sorna V, Warner SL, Bearss DJ, Sharma S, Stephens B. Substituted (E)-N′-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors. Patent WO 2013/025805 A1, University of Utah Research Foundation. 2013.
183. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010;53(7):2719-2740.
184. Sakane C, Okitsu T, Wada A, Sagami H, Shidoji Y. Inhibition of lysine-specific demethylase 1 by the acyclic diterpenoid geranylgeranoic acid and its derivatives. Biochem Biophys Res Commun 2014;444(1):24-29.